all news stories

TOLREMO therapeutics Completes $39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest

Tolremo has completed its Series A financing, bringing the total amount raised to $39 million (CHF 34.1 million). BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors. The Series A round will be used to fund a Phase I trial for its lead candidate in solid tumors. The company is looking to address the problem of drug-resistant cancer.